• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化细胞因子白细胞介素 2 浓度、接种密度和免疫细胞磁珠与细胞比例以用于过继性免疫治疗。

Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy.

机构信息

Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

BMC Immunol. 2021 Jul 3;22(1):43. doi: 10.1186/s12865-021-00435-7.

DOI:10.1186/s12865-021-00435-7
PMID:34217218
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8254233/
Abstract

BACKGROUND

The successful ex vivo expansion of T-cells in great numbers is the cornerstone of adoptive cell therapy. We aimed to achieve the most optimal T-cell expansion condition by comparing the expansion of T-cells at various seeding densities, IL-2 concentrations, and bead-to-cell ratios. we first expanded the peripheral blood mononuclear cells (PBMCs) of a healthy donor at a range of 20 to 500 IU/mL IL-2 concentrations, 125 × 10 to 1.5 × 10 cell/mL, and 1:10 to 10:1 B:C (Bead-to-cell) ratios and compared the results. We then expanded the PBMC of three healthy donors using the optimized conditions and examined the growth kinetics. On day 28, CD3, CD4, and CD8 expression of the cell populations were analyzed by flow cytometry.

RESULTS

T-cells of the first donor showed greater expansion results in IL-2 concentrations higher than 50 IU/mL compared to 20 IU/mL (P = 0.02). A seeding density of 250 × 10 cell/mL was superior to higher or lower densities in expanding T-cells (P = 0.025). Also, we witnessed a direct correlation between the B:C ratio and T-cell expansion, in which, in 5:1 and 10:1 B:C ratios T-cell significantly expanded more than lower B:C ratios. The results of PBMC expansions of three healthy donors were similar in growth kinetics. In the optimized condition, 96-98% of the lymphocyte population expressed CD3. While the majority of these cells expressed CD8, the mean expression of CD4 in the donors was 19.3, 16.5, and 20.4%.

CONCLUSIONS

Our methodology demonstrates an optimized culture condition for the production of large quantities of polyclonal T-cells, which could be useful for future clinical and research studies.

摘要

背景

成功地大量扩增 T 细胞是过继细胞疗法的基石。我们旨在通过比较不同接种密度、IL-2 浓度和珠细胞比的 T 细胞扩增情况,找到最佳的 T 细胞扩增条件。我们首先在 20 至 500 IU/mL 的 IL-2 浓度、125×10 至 1.5×10 细胞/mL 和 1:10 至 10:1 的 B:C(珠细胞比)范围内,对一名健康供体的外周血单核细胞(PBMC)进行扩增,并比较结果。然后,我们使用优化的条件对三名健康供体的 PBMC 进行扩增,并检查生长动力学。在第 28 天,通过流式细胞术分析细胞群体中 CD3、CD4 和 CD8 的表达。

结果

与 20 IU/mL 相比,第一供体的 T 细胞在高于 50 IU/mL 的 IL-2 浓度下显示出更大的扩增效果(P=0.02)。250×10 细胞/mL 的接种密度优于较高或较低的细胞密度(P=0.025)。此外,我们还观察到 B:C 比与 T 细胞扩增之间存在直接相关性,其中在 5:1 和 10:1 的 B:C 比下,T 细胞的扩增明显高于较低的 B:C 比。三名健康供体的 PBMC 扩增结果在生长动力学上相似。在优化条件下,96-98%的淋巴细胞群体表达 CD3。虽然这些细胞中的大多数表达 CD8,但供体的 CD4 平均表达水平为 19.3、16.5 和 20.4%。

结论

我们的方法为生产大量多克隆 T 细胞提供了优化的培养条件,这可能对未来的临床和研究研究有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/1b3a15d4c39c/12865_2021_435_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/3470dae91b60/12865_2021_435_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/b03d117b24f7/12865_2021_435_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/e744e04bd9e5/12865_2021_435_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/3f385f02626b/12865_2021_435_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/705512d73f1d/12865_2021_435_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/1b3a15d4c39c/12865_2021_435_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/3470dae91b60/12865_2021_435_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/b03d117b24f7/12865_2021_435_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/e744e04bd9e5/12865_2021_435_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/3f385f02626b/12865_2021_435_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/705512d73f1d/12865_2021_435_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2954/8254233/1b3a15d4c39c/12865_2021_435_Fig6_HTML.jpg

相似文献

1
Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy.优化细胞因子白细胞介素 2 浓度、接种密度和免疫细胞磁珠与细胞比例以用于过继性免疫治疗。
BMC Immunol. 2021 Jul 3;22(1):43. doi: 10.1186/s12865-021-00435-7.
2
Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.利用抗CD3/CD28、白细胞介素-7和白细胞介素-15对树突状细胞激活的抗原特异性CD4+ T细胞进行体外扩增:过继性T细胞免疫疗法的潜力
Clin Immunol. 2006 Apr;119(1):21-31. doi: 10.1016/j.clim.2005.11.003. Epub 2006 Jan 9.
3
The Effects of Anti-CD3/CD28 Coated Beads and IL-2 on Expanded T Cell for Immunotherapy.抗CD3/CD28包被磁珠和白细胞介素-2对用于免疫治疗的扩增T细胞的影响
Adv Clin Exp Med. 2016 Sep-Oct;25(5):821-828. doi: 10.17219/acem/35771.
4
Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy.氮杂双膦酸酯封端树枝状大分子对人CD4+ T细胞增殖的调节活性增强了从外周血单核细胞中体外扩增自然杀伤细胞用于免疫治疗的能力。
J Transl Med. 2009 Sep 24;7:82. doi: 10.1186/1479-5876-7-82.
5
Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.用于过继性细胞治疗的多种效应细胞群体体外扩增临床模型的开发。
Cytotherapy. 2008;10(1):30-7. doi: 10.1080/14653240701762398.
6
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.体内启动极大地促进了肿瘤抗原特异性T细胞的扩增。
Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083.
7
Determination of cell expansion and surface molecule expression on anti-CD3/28 expanded CD4 T cells.检测抗 CD3/28 扩增的 CD4 T 细胞的细胞扩增和表面分子表达。
Scand J Immunol. 2019 Nov;90(5):e12808. doi: 10.1111/sji.12808. Epub 2019 Aug 22.
8
Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential.在添加了白细胞介素-7(IL-7)的条件下培养的脐带血细胞表现出更高程度的多功能性和优越的增殖潜力。
J Immunother. 2013 Oct;36(8):432-41. doi: 10.1097/CJI.0b013e3182a802f6.
9
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.先天免疫的替代体外激活与白细胞介素-7协同作用,促使天然识别MUC1、HER2/neu和其他肿瘤相关抗原的CD4+和CD8+人外周血T细胞在抗原驱动下快速增殖。
Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.
10
[Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].[白细胞介素-12恢复并促进受5-氟尿嘧啶抑制的T细胞免疫功能]
Ai Zheng. 2007 Aug;26(8):801-8.

引用本文的文献

1
Accelerating cell culture media development using Bayesian optimization-based iterative experimental design.使用基于贝叶斯优化的迭代实验设计加速细胞培养基开发
Nat Commun. 2025 Jul 1;16(1):6055. doi: 10.1038/s41467-025-61113-5.
2
Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium.在无血清培养基中使用BX795和瑞舒伐他汀提高CAR-T细胞生产效率
Int J Mol Sci. 2025 Mar 25;26(7):2988. doi: 10.3390/ijms26072988.
3
γδ T Cells: Game Changers in Immune Cell Therapy for Cancer.γδ T细胞:癌症免疫细胞治疗中的变革者。

本文引用的文献

1
Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells.用于 T 淋巴细胞临床规模扩增的生物反应器系统的目标、益处和挑战。
Biotechnol Adv. 2021 Jul-Aug;49:107735. doi: 10.1016/j.biotechadv.2021.107735. Epub 2021 Mar 26.
2
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.CRISPR 编辑的 T 细胞治疗难治性非小细胞肺癌患者的安全性和可行性。
Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27.
3
CRISPR-engineered T cells in patients with refractory cancer.
Cancers (Basel). 2025 Mar 21;17(7):1063. doi: 10.3390/cancers17071063.
4
CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View.用于血液系统肿瘤和实体瘤的CAR-T细胞制造:从临床前到临床的视角
Cancer Med. 2025 Mar;14(5):e70726. doi: 10.1002/cam4.70726.
5
Clinicopathologic Effects of Xenogeneic GvHD Induced by Adoptively Transferred Human-Derived T Cells in Severely Immunodeficient Mice.通过过继转移人源T细胞在严重免疫缺陷小鼠中诱导的异种移植物抗宿主病的临床病理效应
Arch Iran Med. 2024 Dec 1;27(12):683-692. doi: 10.34172/aim.28597.
6
Effects of virus-induced immunogenic cues on oncolytic virotherapy.病毒诱导的免疫原性线索对溶瘤病毒治疗的影响。
Sci Rep. 2024 Nov 21;14(1):28861. doi: 10.1038/s41598-024-80542-8.
7
Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.专注于外泌体以克服CAR-T细胞疗法现有的瓶颈。
Inflamm Regen. 2024 Nov 4;44(1):45. doi: 10.1186/s41232-024-00358-x.
8
Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.脂肪酸合酶(FASN)是一种限制T细胞免疫的肿瘤细胞内在代谢检查点。
Cell Death Discov. 2024 Sep 30;10(1):417. doi: 10.1038/s41420-024-02184-z.
9
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review.嵌合抗原受体T细胞(CAR-T)疗法中基因编辑技术的进展与陷阱:最新综述
Front Oncol. 2024 Jun 7;14:1388475. doi: 10.3389/fonc.2024.1388475. eCollection 2024.
10
Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.乳腺癌浸润肿瘤淋巴细胞中优势 T 细胞克隆型的持久性和富集。
Br J Cancer. 2024 Jul;131(1):196-204. doi: 10.1038/s41416-024-02707-6. Epub 2024 May 15.
经 CRISPR 基因编辑的 T 细胞治疗难治性癌症的患者。
Science. 2020 Feb 28;367(6481). doi: 10.1126/science.aba7365. Epub 2020 Feb 6.
4
Impact of various culture conditions on ex vivo expansion of polyclonal T cells for adoptive immunotherapy.各种培养条件对过继免疫疗法中多克隆 T 细胞体外扩增的影响。
APMIS. 2019 Dec;127(12):737-745. doi: 10.1111/apm.12981. Epub 2019 Oct 21.
5
Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects.用白细胞介素-7/白细胞介素-15扩增的嵌合抗原受体T(CAR-T)细胞介导更强的抗肿瘤作用。
Protein Cell. 2019 Oct;10(10):764-769. doi: 10.1007/s13238-019-0643-y.
6
Applications of molecular engineering in T-cell-based immunotherapies.分子工程在基于 T 细胞的免疫疗法中的应用。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Sep;11(5):e1557. doi: 10.1002/wnan.1557. Epub 2019 Apr 10.
7
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.生成靶向 CD19 的嵌合抗原受体 T 细胞。
Arch Iran Med. 2019 Jan 1;22(1):7-10.
8
CAR T-cells: costs, comparisons, and commentary.嵌合抗原受体T细胞:成本、比较与评论
J Med Econ. 2019 Jul;22(7):613-615. doi: 10.1080/13696998.2019.1582059. Epub 2019 Mar 21.
9
Adoptive cellular therapies: the current landscape.过继性细胞疗法:现状。
Virchows Arch. 2019 Apr;474(4):449-461. doi: 10.1007/s00428-018-2484-0. Epub 2018 Nov 23.
10
Principles of adoptive T cell therapy in cancer.癌症过继性 T 细胞治疗的原则。
Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5.